Skip to main
HURA
HURA logo

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences Inc. is positioned favorably in the immuno-oncology sector, given its focus on developing innovative solutions to combat resistance to existing cancer therapies. The upcoming Phase 3 registration trial for its personalized cancer vaccine candidate, IFx-2.0, as an adjunctive therapy to Keytruda, signifies a strategic entry into a lucrative market segment, highlighting the company's potential for substantial revenue generation. The company's advancements and pipeline developments underscore its capacity to address unmet medical needs, enhancing the long-term viability and investor interest in TuHURA’s stock.

Bears say

TuHURA Biosciences reported a net loss of $0.15 per share for the first quarter of 2025, which aligns closely with previous estimates but highlights ongoing financial challenges. The company faces significant risks, including possible negative clinical results for its personalized cancer vaccine candidate IFx-2.0, delays in advancing its pipeline candidates, and challenges in obtaining timely regulatory approvals. Additionally, competitive threats from other checkpoint inhibitors and the potential for long-term dilution raise concerns about the company's future profitability and market position.

HURA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 2 analysts, HURA has a Strong Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.